Unity Biotechnology
UBX was delisted on the 8th of July, 2025.
46 hedge funds and large institutions have $5.24M invested in Unity Biotechnology in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 15 closing their positions.
4,547% more call options, than puts
Call options by funds: $2.28M | Put options by funds: $49K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
13.5% less ownership
Funds ownership: 35.55% → 22.05% (-13%)
15% less funds holding
Funds holding: 54 → 46 (-8)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
97% less capital invested
Capital invested by funds: $153M → $5.24M (-$148M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$854K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$321K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$150K |
| 4 |
BlackRock
New York
|
+$149K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.64M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.9M |
| 3 |
FFVM
Founders Fund V Management
San Francisco,
California
|
-$1.77M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$685K |
| 5 |
6CM
683 Capital Management
New York
|
-$658K |
UBX Hedge Fund Activity: Q1 2023 in Review
46 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q1 2023, worth a combined $5.24M — down 97% from $153M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of UBX and 7 opened new positions — a net loss of 8 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was UBS O'Connor, opening a new position worth an estimated $854K. The largest seller was Alyeska Investment Group, cutting an estimated $2.64M.
- 46 institutional investors held Unity Biotechnology (UBX) as of Q1 2023, down from 54 in Q4 2022.
- Funds reported $5.24M of Unity Biotechnology stock for Q1 2023, down 97% quarter-over-quarter.
- 7 funds opened new Unity Biotechnology positions in Q1 2023 and 15 closed out, a net change of -8 holders.
- The largest Unity Biotechnology buyer in Q1 2023 was UBS O'Connor, an estimated $854K added.
- The largest Unity Biotechnology seller in Q1 2023 was Alyeska Investment Group, an estimated $2.64M sold.
Based on aggregated 13F filings for Q1 2023.